基金概述
ARK Genomic Revolution ETF (ARKG) is categorized within the Health sector and is managed by the ARK ETF Trust. This specialized fund currently oversees approximately $1.30 billion in total assets under management, a scale that reflects its established presence among thematic investment vehicles targeting genomic technologies and life sciences. Regarding diversification, the specific number of holdings is not publicly disclosed in the available data, which means the exposure concentration or breadth cannot be directly quantified from these metrics alone. The fund charges an expense ratio of 0.8%, which is notably higher than the industry average for passive index funds, indicating a higher cost structure typical of actively managed thematic strategies that seek to capture specific market inefficiencies rather than replicate broad benchmarks.
业绩分析
The current annualized yield for ARKG is 0.0%, a figure that indicates the fund does not generate significant passive income through dividends, making it less suitable for investors primarily seeking income generation or yield enhancement within their portfolios. On a year-to-date basis, the fund has recorded a return of 3.5%, suggesting a modest positive performance in the current fiscal year relative to its inception or recent benchmarks. When examining longer-term consistency, the 3-year average return stands at -4.4% while the 5-year average return is -21.5%, highlighting a pattern of negative cumulative performance over multi-year horizons. This stark contrast between the positive year-to-date gain and the negative long-term averages suggests that recent short-term market movements may be decoupled from the fund's historical trajectory, potentially driven by specific sector rotations or volatility in the genomic technology sector. The high expense ratio of 0.8% further impacts net returns over time; over a five-year period, this fee structure would have eroded a significant portion of gross gains, contributing to the substantial negative average returns observed in the 5-year metric compared to lower-cost alternatives that might have preserved capital more effectively under similar market conditions.
Price & Risk Profile
The security has traded between a 52-week low of $17.50 and a 52-week high of $34.39, defining a price range of $16.89 that indicates significant price volatility over the past year. To determine the current price position, one must note that without the real-time current price listed in the provided facts, an exact percentage calculation within the range cannot be performed, though the wide spread between the high and low suggests the asset is subject to substantial fluctuation. The beta value is listed as N/A, meaning the fund's volatility relative to the broader market benchmark is not explicitly quantified in the available data, preventing a direct comparison to a standard market index. Based on the wide 52-week trading range and the negative average returns over both 3-year and 5-year periods, the overall risk profile appears to be high, characterized by significant price swings and a history of underperformance, which aligns with the speculative nature of investing in emerging genomic revolution themes.